(S)-Cbz-Phenylalaninol

(S)-Cbz-Phenylalaninol Structure
(S)-Cbz-Phenylalaninol structure
Common Name (S)-Cbz-Phenylalaninol
CAS Number 6372-14-1 Molecular Weight 285.338
Density 1.2±0.1 g/cm3 Boiling Point 489.0±45.0 °C at 760 mmHg
Molecular Formula C17H19NO3 Melting Point 90-94ºC
MSDS Chinese USA Flash Point 249.6±28.7 °C

Preparation of Aminoalkyl Chlorohydrin Hydrochlorides: Key Building Blocks for Hydroxyethylamine-Based HIV Protease Inhibitors.

J. Org. Chem. 61 , 3635, (1996)

Enantiomerically pure N,N-dibenzyl-alpha-amino aldehydes reacted with (chloromethyl)lithium, generated in situ from bromochloromethane and lithium metal, to give predominantly erythro aminoalkyl epoxides. Treatment of the crude epoxides with aqueous hydrochlo...

Stereoselective Synthesis of HIV-1 Protease Inhibitor, DMP 323.

J. Org. Chem. 61 , 444, (1996)

DMP 323, a potent HIV-1 protease inhibitor, has been synthesized by an efficient stereoselective process, amenable to large scale preparations. The core C(2) symmetric diol was synthesized by a stereoselective pinacol coupling of CBZ protected D-phenylalanine...

Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.

J. Med. Chem. 39 , 3514, (1996)

High-resolution X-ray structures of the complexes of HIV-1 protease (HIV-1PR) with peptidomimetic inhibitors reveal the presence of a structural water molecule which is hydrogen bonded to both the mobile flaps of the enzyme and the two carbonyls flanking the ...

Inhibitors of HIV-1 proteinase containing 2-heterosubstituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity.

J. Med. Chem. 37 , 3079, (1994)

A convenient procedure for the synthesis of 2-heterosubstituted statine derivatives as novel building blocks in HIV-protease inhibitors has been developed. The synthesis starts with protected L-phenylalaninols, which were converted to gamma-amino alpha, beta-...

Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.

Chem. Biol. 3 , 301, (1996)

Effective HIV protease inhibitors must combine potency towards wild-type and mutant variants of HIV with oral bioavailability such that drug levels in relevant tissues continuously exceed that required for inhibition of virus replication. Computer-aided desig...

Aldrichimica Acta 28 , 13, (1995)

Liu, C. et al.

Org. Process Res. Dev. 1 , 45, (1997)